Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
71.53 USD | +1.02% |
|
+5.68% | -11.60% |
12:26pm | Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating | MT |
Jul. 11 | Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.60% | 88.22B | |
+63.01% | 856B | |
+38.95% | 631B | |
-4.03% | 359B | |
+16.47% | 325B | |
+8.87% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.35% | 177B | |
+2.07% | 165B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Transcript : Gilead Sciences, Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-11-2021 12